Biotech company Saniona recently announced that the Phase 1 pharmacokinetic study of a new tablet therapy candidate for Prader-Willi syndrome,…
Articles by Patrícia Silva, PhD
A multicenter, Phase 3 clinical trial assessing diazoxide choline controlled-release (DCCR) for the treatment of Prader-Willi syndrome (PWS) recently was…
Saniona obtained regulatory approval to initiate the second part of a Phase 2a study evaluating the investigative therapy Tesomet (tesofensine/metoprolol)…
The Prader-Willi California Foundation is hosting its 18th Annual Walking for Prader-Willi Syndrome events in April, May,…
Soleno Therapeutics and the U.S. Food and Drug Administration recently held a meeting to mark the end of a…
Saniona recently reported encouraging results from its exploratory Phase 2a clinical trial evaluating Tesomet (tesofensine/metoprolol) in patients with…